Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

Exclusion Criteria

• •Has nonepithelial cancers, borderline tumors, mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor and undifferentiated carcinoma.
• •Has primary platinum-refractory disease, defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of first-line platinum-based therapy.
• •Has prior disease progression on weekly paclitaxel alone.
• •Has received \>2 prior lines of systemic therapy for OC.
• •Has received prior systemic anticancer therapy including investigational agents or maintenance therapy (including bevacizumab maintenance therapy), within 4 weeks before randomization.
• •Has received prior radiation therapy within 2 weeks of start of study intervention.
• •Has not recovered adequately from surgery and/or any complications from the surgery.
• •Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor,\[GM-CSF\] or recombinant erythropoietin) within 4 weeks before randomization.
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
• •Has received investigational agent or has used an investigational device within 4 weeks prior to study intervention.
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
• •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• •Has severe hypersensitivity (≥Grade 3) to pembrolizumab, paclitaxel, or bevacizumab (if using) and/or any of their excipients.
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years.
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• •Has an active infection requiring systemic therapy.
• •Has a known history of human immunodeficiency virus (HIV) infection.
• •Has a known history of Hepatitis B or known active Hepatitis C virus infection.
• •Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study.
• •Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
• •Participant, in the judgement of the investigator, is unlikely to comply with the study procedures, restrictions, and requirements of the study.
• •Has had an allogenic tissue/solid organ transplant.
• •For bevacizumab treatment
• •Has uncontrolled hypertension.
• •Has current, clinically relevant bowel obstruction including related to underlying epithelial OC, abdominal fistula or gastrointestinal perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam.
• •Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active gastrointestinal bleeding within 6 months before randomization.